Figure 4.

miR-134 regulates KRAS and STAT5B expressions by directly binding to their mRNA 3′UTRs. (a) Alignment of KRAS, STAT5B 3′UTRs and miR-134 sequences showing the predicted binding sites. The sites of targeted mutagenesis for the generation of mutant controls are indicated by the arrows. (b) Immunoblots (left panel) showing the effects of miR-134 overexpression on the protein levels of KRAS and STAT5B in GBM cells and GSCs. Immunoblots (right panel) showing the effects of miR-134 inhibition with anti-miR-134 on the protein levels of KRAS and STAT5B in GBM cells. (c) Quantitative RT-PCR showing the effects of miR-134 and anti-miR-134 on the mRNA levels of STAT5B and KRAS. (d) 3′UTR luciferase assays for KRAS and STAT5B showing the inhibition of luciferase activity by miR134 in GBM cells. No significant alteration in luciferase activity was observed when 3′UTR binding site was mutated. *P<0.05